{
    "clinical_study": {
        "@rank": "116054", 
        "acronym": "imm03", 
        "arm_group": [
            {
                "arm_group_label": "V7: Heat-inactivated M. vaccae pill", 
                "arm_group_type": "Experimental", 
                "description": "Daily pill of V7 together with standard tuberculosis therapy"
            }, 
            {
                "arm_group_label": "Placebo pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "one pill of placebo pill once per day together with standard of care TB drugs"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to identify optimally effective dose of whole-cell, heat-killed\n      Mycobacterium vaccae formulated as a pill and consequently carry out multi-country,\n      placebo-controlled, randomized Phase III trial in patients with drug-sensitive, multi-drug\n      resistant (MDR-TB) and TB-HIV."
        }, 
        "brief_title": "TB Immunotherapy Trial With Heat-killed M. Vaccae", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Tuberculosis", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  confirmed diagnosis of TB\n\n          -  sputum smear positive\n\n        Exclusion Criteria:\n\n          -  pregnant\n\n          -  likely to be non-compliant due to drug and/or alcohol abuse\n\n          -  mentally unfit to comply with treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "440", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977768", 
            "org_study_id": "imm03", 
            "secondary_id": "imm03"
        }, 
        "intervention": [
            {
                "arm_group_label": "V7: Heat-inactivated M. vaccae pill", 
                "description": "One pill of V7 once daily for 30 days together with standard of care TB drugs", 
                "intervention_name": "V7", 
                "intervention_type": "Biological", 
                "other_name": "V7 or tableted heat-inactivated mycobacterium vaccae"
            }, 
            {
                "arm_group_label": "Placebo pill", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "M. vaccae", 
            "TB", 
            "MDR-TB", 
            "V7-immunitor"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "contact": {
                "email": "tb_doctor@mail.ru", 
                "last_name": "Dmytro Butov, MD, PhD", 
                "phone": "380977723777"
            }, 
            "facility": {
                "address": {
                    "city": "Kharkiv", 
                    "country": "Ukraine", 
                    "zip": "60071"
                }, 
                "name": "Kharkiv Medical National University"
            }, 
            "investigator": {
                "last_name": "Dmytro Butov, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Ukraine"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III and Dose Ranging Trial of Heat-killed M. Vaccae (V7)", 
        "other_outcome": {
            "description": "Identify changes in immune cells subsets and cytokine profile resulting from V7 administration", 
            "measure": "Immune correlates", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "overall_contact": {
            "email": "tb_doctor@mail.ru", 
            "last_name": "Dmytro Butov, MD, PhD", 
            "phone": "380977723777"
        }, 
        "overall_contact_backup": {
            "email": "info@immunitor.com", 
            "last_name": "Aldar Bourinbaiar, PhD, MD/PhD", 
            "phone": "13014760930"
        }, 
        "overall_official": {
            "affiliation": "Immunitor LLC", 
            "last_name": "Aldar Bourinbaiar, PhD, MD/PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Ukraine: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "bacillary sputum smear clearance", 
            "safety_issue": "Yes", 
            "time_frame": "two years"
        }, 
        "reference": [
            {
                "PMID": "24088075", 
                "citation": "Butov DA, Efremenko YV, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Butova TS, Stepanenko AL, Kutsyna GA, Jirathitikal V, Bourinbaiar AS. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7). Immunotherapy. 2013 Oct;5(10):1047-54. doi: 10.2217/imt.13.110."
            }, 
            {
                "PMID": "23782489", 
                "citation": "Efremenko YV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Butova TS, Stepanenko AL, Kutsyna GA, Jirathitikal V, Bourinbaiar AS. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7). Hum Vaccin Immunother. 2013 Jun 19;9(9). [Epub ahead of print]"
            }, 
            {
                "PMID": "22397570", 
                "citation": "Bourinbaiar AS, Mezentseva MV, Butov DA, Nyasulu PS, Efremenko YV, Jirathitikal V, Mishchenko VV, Kutsyna GA. Immune approaches in tuberculosis therapy: a brief overview. Expert Rev Anti Infect Ther. 2012 Mar;10(3):381-9. doi: 10.1586/eri.12.1. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977768"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "comparison of body weight changes between treatment arm and placebo", 
                "measure": "changes in body weight", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "changes in Erythrocyte Sedimentation Rate and leukocyte counts", 
                "measure": "changes in inflammation markers", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Lisichansk Regional Tuberculosis Dispensary", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Medical University, Ukraine", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Immunitor USA Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Monash University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Lisichansk Regional Tuberculosis Dispensary", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}